Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARESTIN vs AMZEEQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Minocycline is a semisynthetic tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the elongating peptide chain. This action is bacteriostatic. In periodontal disease, it also inhibits matrix metalloproteinases (MMPs), particularly collagenase, and suppresses inflammatory cytokine production, reducing tissue destruction.
Topical antibiotic and anti-inflammatory: inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, and reduces pro-inflammatory cytokine production.
Adjunctive treatment of periodontitis (subgingival administration by a dental professional),Off-label: Treatment of acne vulgaris, rosacea, rheumatoid arthritis (MRSA decolonization is not standard)
FDA-approved for the treatment of inflammatory lesions of rosacea
1 mg subgingival application per periodontal pocket, applied as a single dose by a dental professional.
Apply a thin layer to affected areas twice daily (morning and evening). Topical, 1.5% w/w.
The terminal elimination half-life of minocycline is 11-17 hours (mean ~16 hours). This long half-life allows for twice-daily dosing in systemic use, but for Arestin (subgingival), local sustained release provides prolonged local exposure.
Terminal half-life is approximately 28 days due to accumulation in the skin and hair follicles; clinical context: supports once-weekly dosing.
Minocycline is extensively metabolized in the liver via multiple pathways, with at least 6 metabolites identified. The major metabolic routes include hydroxylation at the 9-position (via CYP450 enzymes, possibly CYP3A4) and N-demethylation. It also undergoes glucuronidation. The drug has a long half-life (11–17 hours) and undergoes enterohepatic recirculation.
Minimal systemic absorption; not extensively metabolized.
Minocycline is primarily eliminated via hepatic metabolism and biliary/fecal excretion. Renal excretion accounts for approximately 10-20% of the dose, with the remainder excreted in feces via bile. Less than 10% is recovered unchanged in urine.
Renal: 30% as unchanged drug; Fecal: 70% as metabolites and unchanged drug via biliary excretion.
Minocycline is approximately 70-75% bound to plasma proteins.
99% bound to plasma proteins, primarily albumin and lipoproteins.
Volume of distribution for minocycline is 1.0-1.3 L/kg, indicating extensive tissue penetration, consistent with its lipophilic nature and ability to concentrate in various tissues including gingival crevicular fluid.
Approximately 12 L/kg, indicating extensive distribution into tissues including skin and sebaceous glands.
Subgingival administration: Direct local delivery results in negligible systemic absorption (bioavailability <1% relative to oral dose). Oral minocycline bioavailability is approximately 90-100%.
Topical: Minimal systemic absorption, approximately 1% of applied dose.
No dose adjustment required for renal impairment.
No dosage adjustment required for renal impairment.
No dose adjustment required for hepatic impairment.
No dosage adjustment required for hepatic impairment.
Not recommended in pediatric patients below 18 years of age due to lack of safety and efficacy data.
Not recommended for patients under 12 years of age; safety and efficacy not established.
No specific dose adjustment; use with caution due to potential age-related comorbidities.
No specific dose adjustment; use same as adults with caution for skin fragility.
None.
No black box warning.
Photosensitivity: May cause exaggerated sunburn; avoid prolonged sun exposure.,Superinfection: Use may result in overgrowth of nonsusceptible organisms, including fungi.,Hepatotoxicity: Rare cases of liver injury; discontinue if symptoms occur.,Renal impairment: Use with caution in renal dysfunction; may accumulate.,Autoimmune syndromes: Cases of drug-induced lupus, serum sickness-like reactions, and vasculitis reported.,Intracranial hypertension: Associated with minocycline; symptoms include headache and blurred vision.,Tooth discoloration: May cause permanent discoloration of teeth in children under 8 years.,Bone development: Use during pregnancy may affect fetal skeletal development.
Use may result in overgrowth of nonsusceptible organisms including fungi.,Avoid contact with eyes, mouth, and mucous membranes.,Not for oral, ophthalmic, or intravaginal use.
Hypersensitivity to any tetracycline antibiotic.,Pregnancy (especially second and third trimesters) – risk of fetal harm.,Lactation – excreted in breast milk, potential for adverse effects in nursing infants.,Children under 8 years of age – risk of permanent tooth discoloration.
Hypersensitivity to any component of the formulation.
No known food interactions. Patients should avoid hard, crunchy, or sticky foods for at least 7 days after application to prevent mechanical disruption of the microspheres.
No significant food interactions reported with topical AMZEEQ. However, oral minocycline absorption is affected by dairy products; for topical foam, no dietary restrictions are necessary.
ARESTIN (minocycline hydrochloride) is a tetracycline antibiotic. Class D: Positive evidence of human fetal risk. Use contraindicated in pregnancy. Risk is highest in second and third trimesters due to tetracycline deposition in fetal bones and teeth, causing permanent discoloration and enamel hypoplasia. Potential for reversible inhibition of bone growth. First trimester exposure may be associated with neural tube defects and cardiac malformations, though data are limited.
Limited human data; animal studies show no teratogenic effects at systemic exposures up to 1.7 times the MRHD. No known fetal risk; avoid first trimester due to theoretical risk from systemic absorption.
Minocycline is excreted into human breast milk with an M/P ratio of approximately 0.6 to 0.8. Theoretical risk of permanent tooth discoloration and bone growth inhibition in nursing infants. Avoid use in breastfeeding women; if necessary, consider temporary cessation of breastfeeding. Alternative antibiotics are preferred.
Unknown if excreted in human milk; M/P ratio not available. Use with caution; avoid application to breast area.
Pregnancy is a contraindication; ARESTIN should not be used. Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced clearance) may reduce minocycline levels, but no dose adjustments are recommended because the drug is contraindicated. No studies establish safe dosing in pregnancy.
No dosage adjustment required; pharmacokinetics in pregnancy not studied.
ARESTIN (minocycline microspheres) is a locally administered antibiotic adjunct to scaling and root planing (SRP) for periodontitis. Do not use in patients with known hypersensitivity to tetracyclines. Avoid placement in areas with active abscesses. Apply only into periodontal pockets ≥5 mm. Do not pack deeply; overfill may cause tissue irritation. No systemic antibiotic effect; monitor for local adverse effects like pain or swelling.
AMZEEQ (minocycline) 4% foam is a topical antibiotic indicated for inflammatory lesions of rosacea. Avoid contact with eyes and mucous membranes. Use once daily. May cause skin yellowing (pseudolacte) and hyperpigmentation, especially in dark-skinned patients. Consider sunscreen use due to photosensitivity risk. Not for oral administration.
Do not brush, floss, or use interdental cleaners in the treated area for 7 days after application.,Avoid eating hard, crunchy, or sticky foods for 1 week to prevent dislodging the microspheres.,Some minor discomfort, redness, or swelling at the application site is normal and usually resolves within days.,Report severe pain, swelling, or signs of infection (e.g., pus, fever) to your dentist promptly.,Continue routine oral hygiene in untreated areas as directed by your dentist.
Apply foam to affected areas of face once daily, avoiding eyes and mouth.,Wash hands after application.,May cause temporary yellowing of skin or fingernails; not harmful.,Use sunscreen and protective clothing to prevent sunburn.,Do not swallow or apply to large skin areas.,Inform doctor if pregnant, breastfeeding, or planning pregnancy.,Avoid using other topical products on treated areas unless directed by doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARESTIN vs AMZEEQ, answered by our medical review team.
ARESTIN is a Tetracycline Antibiotic that works by Minocycline is a semisynthetic tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the elongating peptide chain. This action is bacteriostatic. In periodontal disease, it also inhibits matrix metalloproteinases (MMPs), particularly collagenase, and suppresses inflammatory cytokine production, reducing tissue destruction.. AMZEEQ is a Tetracycline Antibiotic that works by Topical antibiotic and anti-inflammatory: inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, and reduces pro-inflammatory cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARESTIN and AMZEEQ depend on the specific clinical indication. These are both Tetracycline Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARESTIN is: 1 mg subgingival application per periodontal pocket, applied as a single dose by a dental professional.. The standard adult dose of AMZEEQ is: Apply a thin layer to affected areas twice daily (morning and evening). Topical, 1.5% w/w.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARESTIN and AMZEEQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARESTIN is classified as Category C. ARESTIN (minocycline hydrochloride) is a tetracycline antibiotic. Class D: Positive evidence of human fetal risk. Use contraindicated in pregnancy. Risk is highest in second and th. AMZEEQ is classified as Category C. Limited human data; animal studies show no teratogenic effects at systemic exposures up to 1.7 times the MRHD. No known fetal risk; avoid first trimester due to theoretical risk fr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.